狼疮肾炎蛋白质组学和代谢组学的研究进展-东南大学学报医学版

狼疮肾炎蛋白质组学和代谢组学的研究进展

单位：1. 南京医科大学第一附属医院风湿免疫科, 江苏南京 210029;
2. 南京医科大学附属淮安第一医院风湿免疫科, 江苏淮安 223300;
3. 南京医科大学附属淮安第一医院肾内科, 江苏淮安 223300

分类号：R593.2

出版年·卷·期（页码）：2016·35·第五期（789-792）

摘要：

狼疮肾炎（LN）是系统性红斑狼疮（SLE）最严重的表现之一，肾脏损害的严重程度与SLE的预后密切相关。LN发病涉及到多种因素，包括遗传易感性、表观遗传调控和环境。近十来年基于组学的技术（包括基因组学、转录组学、蛋白质组学、代谢组学）已广泛地用于SLE及LN生物标志物筛选和疾病的分型分类。这些研究深化了我们对疾病分子基础的认识，对识别潜在治疗靶点、疾病的早期预测及治疗非常重要。本文作者就最近几年狼疮肾炎蛋白质组学及代谢组学的相关研究进展作一综述。

参考文献：

[1] 秦燕萍,王美美.Smad4、Smad7在慢性GVHD狼疮肾炎模型小鼠肾组织的异常表达[J].东南大学学报:医学版,2007,26(2):107-111.
[2] 黄劬,宋文娟,刘殿阁.59例狼疮性肾炎临床病理资料分析[J].东南大学学报:医学版,2010,29(6):673-677.
[3] LIU C C,MANZI S,AHEARN J M.Biomarkers for systemic lupus erythematosus:a review and perspective[J].Curr Opin Rheumatol,2005,17(5):543-549.
[4] MARCHINI M,ANTONIOLI R,LLEÒ A,et al.HLA class II antigens assoiated with lupus nephritis in italian SLE patients[J].Hum Immunol,2003,64(4):462-468.
[5] HARLEY J B,ALARCÓN-RIQUELME M E,CRISWELL L A,et al.Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM,PXK,KIAA1542 and other loci[J].Nat Genet,2009,40(2):204-210.
[6] MORGAN P E,STURGESS A D,HENNESSY A,et al.Serum protein oxidation and apolipoprotein CIII levels in people with systemic lupus erythematosus with and without nephritis [J].Free Radic Res,2007,41(12):1301-1312.
[7] SERADA S,FUJIMOTO M,TAKAHASHI T,et al.Proteomic analysis of autoantigens associated with systemic lupus erythematosus:anti-aldolase A antibody as a potential marker of lupus nephritis [J].Proteomics Clin Appl,2007,1(2):185-191.
[8] PETERSSON L,DEXLIN-MELLBY L,BENGTSSON A A,et al.Multiplexing of miniaturized planar antibody arrays for serum protein profiling-a biomarker discovery in SLE nephritis[J].Lab Chip,2014,14(11):1931-1942.
[9] LI Q Z,XIE C,WU T,et al.Identification of autoantibody clusters that best predict lupus disease activity using glomerular proteome arrays[J].J Clin Invest,2005,115(12):3228-3239.
[10] BRUSCHI M,SINICO R A,MORONI G,et al.Glomerular autoimmune multicomponents of human lupus nephritis in vivo:α-enolase and annexin AI[J].J Am Soc Nephrol,2014,25(11):2483-2498.
[11] ZHANG X,JIN M,WU H,et al.Biomarkers of lupus nephritis determined by serial urine proteomics[J].Kidney Int,2008,74(6):799-807.
[12] JAMES P.Protein identification in the post-genome era:the rapid rise of proteomics[J].Q Rev Biophys,1997,30(4):279-331.
[13] SCHAUB S,WILKINS J,WEILER T,et al.Urine protein profiling with surface-enhanced laser-desorption/ionization time-of-flight mass spectrometry[J].Kidney Int,2004,65(1):323-332.
[14] WU T,MOHAN C.Proteomic toolbox for autoimmunity research[J].Autoimmun Rev,2009,8(7):595-598.
[15] SUZUKI M,WIERS K,BROOKS E B,et al.Initial validation of a novel protein biomarker panel for active pediatric lupus nephritis[J].Pediatr Res,2009,65(5):530-536.
[16] OATES J C,VARGHESE S,BLAND A M,et al.Prediction of urinary protein markers in lupus nephritis[J].Kidney Int,2005,68(6):2588-2592.
[17] UEHARA Y,MAKINO H,SEIKI K,et al.Urinary excretions of lipocalin-type prostaglandin D synthase predict renal injury in type-2 diabetes:a cross-sectional and prospective multicentre study[J].Nephrol Dial Transplant,2009,24(2):475-482.
[18] LEE P,PENG H,GELBART T,et al.Regulation of hepcidin transcription by interleukin-1 and interleukin-6[J].Proc Natl Acad Sci U S A,2005,102(6):1906-1910.
[19] MOSLEY K,TAM F W,EDWARDS R J,et al.Urinary proteomic profiles distinguish between active and inactive lupus nephritis[J].Rheumatology (Oxford),2006,45(12):1497-1504.
[20] LEE P,PENG H,GELBART T,et al.Regulation of hepcidin transcription by interleukin-1 and interleukin-6[J].Proc Natl Acad Sci U S A,2005,102(6):1906-1910.
[21] VARGHESE S A.Urine biomarkers predict the cause of glomerular disease[J].J Am Soc Nephrol,2007,18(3):913-922.
[22] OATES J C,VARGHESE S,BLAND A M,et al.Prediction of urinary protein markers in lupus nephritis[J].Kidney Int,2005,68(6):2588-2592.
[23] WU T,FU Y,BREKKEN D,et al.Urine proteome scans uncover total urinary protease,prostaglandin D synthase,serum amyloid P,and superoxide dismutase as potential markers of lupus nephritis[J].J Immunol,2010,184(4):2183-2193.
[24] SUI W,TANG D,ZOU G,et al.Differential proteomic analysis of renal tissue in lupus nephritis using iTRAQ reagent technology[J].Rheumatol Int,2012,32(11):3537-3543.
[25] ALAIYA A,ASSAD L,ALKHAFAJI D,et al.Proteomic analysis of class IV lupus nephritis[J].Nephrol Dial Transplant,2015,30(1):62-70.
[26] WU T,XIE C,HAN J,et al.Metabolic disturbances associated with systemic lupus erythematosus[J].PLoS One,2012,7(6):e37210.
[27] OUYANG X,DAI Y,WEN J L,et al.¹H NMR-based metabolomic study of metabolic profiling for systemic lupus erythematosus[J].Lupus,2011,20(13):1411-1420.
[28] NOWLING T K,MATHER A R,THIYAGARAJAN T,et al.Renal glycosphingolipid metabolism is dysfunctional in lupus nephritis[J].J Am Soc Nephrol,2015,26(6):1402-1413.
[29] HAMMAD S M.Blood sphingolipids in homeostasis and pathobiology[J].Adv Exp Med Biol,2011,721:57-66.
[31] ALLEY W R Jr,MANN B F,NOVOTNY M V F,et al.High-sensitivity analytical approaches for the structural characterization of glycoproteins[J].Chem Rev,2013,113(4):2668-2732.
[32] ROMICK-ROSENDALE L E,BRUNNER H I,BENNETT M R,et al.Identification of urinary metabolites that distinguish membranous lupus nephritis from proliferative lupus nephritis and focal segmental glomerulosclerosis[J].Arthritis Res Ther,1981,13(6):1-10.
[33] CHRISTIANS U,SCHMITZ V,SCHÖNING W,et al.Toxicodynamic therapeutic drug monitoring of immunosuppressants:promises,reality and challenges[J].Ther Drug Monit,2008,30(2):151-158.
[34] QUAGGIN S E,KREIDBERG J A.Development of the renal glomerulus:good neighbors and good fences[J].Development,2008,135(4):609-620.
[35] 鲁莹,丁朝霞,杨少锋,等.昆仙胶囊对MRL/lpr小鼠狼疮性肾炎的代谢组学研究[J].中药药理与临床,2011,27(1):78-81.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录